Table 3.
Comparison of post-HTx survival among the 3 cohorts.
| Post-HTx survival | ||||||
|---|---|---|---|---|---|---|
| 1-year survival (%±SE) | 2-year survival (%±SE) | HR (95% CI) ‡ | p-value | HR (95% CI) § | p-value | |
| Clinical Course | ||||||
| MED group (n=6676) | 89.9±0.39 | 85.9±0.47 | 1.000 | |||
| Delayed-LVAD group (n=1170) | 88.5±0.98 | 84.5±1.20 | 1.090 (0.926-1.283) | 0.298 | 1.000 | |
| Early-LVAD group (n=1176) | 88.1±1.01 | 84.4±1.24 | 1.181 (1.006-1.387) | 0.042 | 1.083 (0.879-1.335) | 0.453 |
| UNOS status at the time of listing | ||||||
| Listed as UNOS status 1A | ||||||
| MED group (n=1161) | 90.0±0.92 | 85.0±1.18 | 1.000 | |||
| Delayed-LVAD group (n=234) | 92.6±1.78 | 89.2±2.28 | 0.807 (0.542-1.202) | 0.292 | 1.000 | |
| Early-LVAD group (n=593) | 87.7±1.43 | 83.5±1.78 | 1.305 (1.019-1.671) | 0.035 | 1.617 (1.067-2.451) | 0.024 |
| Listed as UNOS status 1B | ||||||
| MED group (n=2748) | 90.5±0.59 | 86.3±0.73 | 1.000 | |||
| Delayed-LVAD group (n=525) | 87.0±1.55 | 82.4±1.90 | 1.235 (0.975-1.564) | 0.081 | 1.000 | |
| Early-LVAD group (n=524) | 89.0±1.47 | 85.7±1.82 | 1.084 (0.837-1.405) | 0.541 | 0.878 (0.639-1.208) | 0.425 |
‡
Comparison analysis being adjusted by age, gender, race, blood type, and coexisting of diabetes mellitus, MED group as a reference
§
Comparison analysis being adjusted by age, gender, race, blood type, and coexisting of diabetes mellitus, Delayed-LVAD group as a reference
HTx indicates heart transplantation; MED, medically treated; LVAD, left ventricular assist device; SE, standard error; HR, hazard ratio; CI, confidential interval.